Tokyo, Japan

Katsuaki Imamura


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2010-2012

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Katsuaki Imamura: Pioneering Advances in Triazole Compounds

Introduction

Katsuaki Imamura is a notable inventor based in Tokyo, Japan. He holds two patents, showcasing his contributions to the field of pharmaceutical innovation. His work primarily focuses on triazole compounds and their applications in therapeutic drugs aimed at treating various metabolic disorders.

Latest Patents

Imamura’s latest patents are centered around triazole compounds, which are significant for their HSD1 inhibitory activity. The first patent details a triazole compound, a prodrug thereof, or a pharmaceutically acceptable salt, which has demonstrated effectiveness as an HSD1 inhibitor. This innovative compound is beneficial in the development of therapeutic drugs for diabetes, obesity, and metabolic syndrome. The second patent similarly emphasizes the advantages of the triazole compound as a therapeutic drug, reinforcing its role in addressing these prevalent health issues.

Career Highlights

Katsuaki Imamura is affiliated with Amgen Inc., a leading biotechnology company focused on discovering, developing, and delivering innovative human therapeutics. Throughout his career, Imamura has demonstrated a commitment to advancing healthcare through his inventive contributions.

Collaborations

At Amgen Inc., Imamura collaborates with other esteemed colleagues, such as Jay Patrick Powers and Mario G Cardozo. These partnerships enhance the innovation processes and bring diverse expertise together to tackle complex medical challenges.

Conclusion

Katsuaki Imamura stands out as a prominent inventor in Tokyo, JP, contributing significantly to the field of pharmaceutical innovations through his patents on triazole compounds. His work exemplifies the intersection of scientific research and practical application in medicine, potentially leading to improved treatments for metabolic disorders. His collaboration with fellow innovators at Amgen Inc. ensures a continued focus on groundbreaking advancements in the healthcare sector.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…